---
title: "無錫藥明康德新藥開發股份有限公司 (02359.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02359.HK.md"
symbol: "02359.HK"
name: "無錫藥明康德新藥開發股份有限公司"
industry: "生命科學工具與服務"
---

# 無錫藥明康德新藥開發股份有限公司 (02359.HK)

| Item | Detail |
|------|--------|
| Industry | 生命科學工具與服務 |
| Location | 港股市場 |
| Website | [www.wuxiapptec.com.cn](https://www.wuxiapptec.com.cn) |

## Company Profile

開發研究及報批新藥,醫藥中間體和精細化工產品(不含危險化學品)的研發;醫藥科技、生物技術、組合化學、有機化學、醫療科技、檢測技術、計算機科技的技術開發、技術轉讓、技術服務和技術咨詢;一類醫療器械、藥品的批發,機械設備及零配件的銷售;自營和代理各類商品及技術的進出口業務(國家限定企業經營或禁止進出口的商品和技術除外);企業管理咨詢、醫藥信息咨詢、健康咨詢(不含診療活動、心理咨詢);房屋租賃;會議及展覽服務;利用自有資金對外投資。(依法須經批准的項目,經相關部門批准後方可開展經營活動)(最終以工商核定為准)

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:12.000Z

**Overall: B (0.26)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 1 / 14 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.91% |  |
| Net Profit YoY | 84.04% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 4.84 |  |
| Dividend Ratio | 1.40% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 375.98B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 47.42B |  |


**Multi Score**: B

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 25.82% | A |
| Profit Margin | 34.17% | A |
| Gross Margin | 49.61% | B |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.91% | A |
| Net Profit YoY | 84.04% | A |
| Total Assets YoY | 25.68% | A |
| Net Assets YoY | 26.81% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 292.67% | C |
| OCF YoY | 21.91% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.52 | C |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 24.45% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 無錫藥明康德新藥開發股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "25.82%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "34.17%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "49.61%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21.91%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "84.04%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "25.68%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "26.81%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "292.67%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "21.91%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "24.45%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 藥明康德 (HK.2359) | A | A | C | B | B | B |
| 02 | 藥明生物 (HK.2269) | B | B | D | A | B | B |
| 03 | 藥明合聯 (HK.2268) | A | A | B | B | B | B |
| 04 | 晶泰控股 (HK.2228) | D | A | E | A | C | B |
| 05 | 康龍化成 (HK.3759) | B | B | C | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 23.47 | 4/15 | 21.62 | 19.60 | 17.58 |
| PB | 4.84 | 12/15 | 4.72 | 3.93 | 2.97 |
| PS (TTM) | 7.73 | 11/15 | 6.91 | 6.22 | 4.37 |
| Dividend Yield | 1.40% | 1/15 | 1.82% | 1.68% | 1.52% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-15T16:00:00.000Z

Total Analysts: **25**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 20 | 80% |
| Overweight | 4 | 16% |
| Hold | 1 | 4% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 126.00 |
| Highest Target | 152.33 |
| Lowest Target | 94.66 |

## References

- [Company Overview](https://longbridge.com/en/quote/02359.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02359.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02359.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.